← Drug database

Avonex (interferon beta-1a)

Region
🇪🇺 EU
Active substance
interferon beta-1a
Company
Biogen Netherlands B.V.
Status
Authorised
Therapeutic area
Multiple Sclerosis
EU approval
Thu 13 Mar 1997
Application
EMEA/H/C/000102
ATC
L03AB07
Official record
www.ema.europa.eu

Indication

Avonex is indicated for the treatment of: patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; Avonex slows the progression of disability and decreases the frequency of relapses; patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite MS. Avonex should be discontinued in patients who develop progressive MS.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Avonex

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.